269 related articles for article (PubMed ID: 23633489)
21. Tumor associated macrophages provide the survival resistance of tumor cells to hypoxic microenvironmental condition through IL-6 receptor-mediated signals.
Jeong SK; Kim JS; Lee CG; Park YS; Kim SD; Yoon SO; Han DH; Lee KY; Jeong MH; Jo WS
Immunobiology; 2017 Jan; 222(1):55-65. PubMed ID: 26705936
[TBL] [Abstract][Full Text] [Related]
22. IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2.
Kurozumi A; Nakano K; Yamagata K; Okada Y; Nakayamada S; Tanaka Y
Bone; 2019 Jul; 124():53-61. PubMed ID: 30981888
[TBL] [Abstract][Full Text] [Related]
23. Enhanced IL-6/IL-6R signaling promotes growth and malignant properties in EBV-infected premalignant and cancerous nasopharyngeal epithelial cells.
Zhang G; Tsang CM; Deng W; Yip YL; Lui VW; Wong SC; Cheung AL; Hau PM; Zeng M; Lung ML; Chen H; Lo KW; Takada K; Tsao SW
PLoS One; 2013; 8(5):e62284. PubMed ID: 23658720
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.
Yan S; Li Z; Thiele CJ
Oncotarget; 2013 Mar; 4(3):433-45. PubMed ID: 23531921
[TBL] [Abstract][Full Text] [Related]
25. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
Colomiere M; Ward AC; Riley C; Trenerry MK; Cameron-Smith D; Findlay J; Ackland L; Ahmed N
Br J Cancer; 2009 Jan; 100(1):134-44. PubMed ID: 19088723
[TBL] [Abstract][Full Text] [Related]
26. Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular.
Legendre F; Bogdanowicz P; Boumediene K; Pujol JP
J Rheumatol; 2005 Jul; 32(7):1307-16. PubMed ID: 15996070
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-6-mediated trans-signaling inhibits transforming growth factor-β signaling in trabecular meshwork cells.
Inoue-Mochita M; Inoue T; Kojima S; Futakuchi A; Fujimoto T; Sato-Ohira S; Tsutsumi U; Tanihara H
J Biol Chem; 2018 Jul; 293(28):10975-10984. PubMed ID: 29752408
[TBL] [Abstract][Full Text] [Related]
28. MiR-125a-5p Decreases the Sensitivity of Treg cells Toward IL-6-Mediated Conversion by Inhibiting IL-6R and STAT3 Expression.
Li D; Kong C; Tsun A; Chen C; Song H; Shi G; Pan W; Dai D; Shen N; Li B
Sci Rep; 2015 Oct; 5():14615. PubMed ID: 26424054
[TBL] [Abstract][Full Text] [Related]
29. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.
Ryu K; Susa M; Choy E; Yang C; Hornicek FJ; Mankin HJ; Duan Z
BMC Cancer; 2010 May; 10():187. PubMed ID: 20459702
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-6-induced epithelial-mesenchymal transition through signal transducer and activator of transcription 3 in human cervical carcinoma.
Miao JW; Liu LJ; Huang J
Int J Oncol; 2014 Jul; 45(1):165-76. PubMed ID: 24806843
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
33. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma.
Tu B; Du L; Fan QM; Tang Z; Tang TT
Cancer Lett; 2012 Dec; 325(1):80-8. PubMed ID: 22743617
[TBL] [Abstract][Full Text] [Related]
34. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells.
Isomoto H; Kobayashi S; Werneburg NW; Bronk SF; Guicciardi ME; Frank DA; Gores GJ
Hepatology; 2005 Dec; 42(6):1329-38. PubMed ID: 16317687
[TBL] [Abstract][Full Text] [Related]
35. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.
Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J
BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581
[TBL] [Abstract][Full Text] [Related]
36. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P.
Horiguchi A; Oya M; Marumo K; Murai M
Kidney Int; 2002 Mar; 61(3):926-38. PubMed ID: 11849447
[TBL] [Abstract][Full Text] [Related]
37. Combination of 4-hydroperoxy cyclophosphamide and methotrexate inhibits IL-6/sIL-6R-induced RANKL expression in fibroblast-like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway.
Niu HQ; Zhao WP; Zhao XC; Luo J; Qin KL; Chen KL; Li XF
Int Immunopharmacol; 2018 Aug; 61():45-53. PubMed ID: 29803913
[TBL] [Abstract][Full Text] [Related]
38. Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.
Dimberg LY; Dimberg A; Ivarsson K; Fryknäs M; Rickardson L; Tobin G; Ekman S; Larsson R; Gullberg U; Nilsson K; Öberg F; Wiklund HJ
BMC Cancer; 2012 Jul; 12():318. PubMed ID: 22838736
[TBL] [Abstract][Full Text] [Related]
39. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF
Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717
[TBL] [Abstract][Full Text] [Related]
40. Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells.
Erices A; Conget P; Rojas C; Minguell JJ
Exp Cell Res; 2002 Oct; 280(1):24-32. PubMed ID: 12372336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
